Cargando…
Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future
Amyloid β protein (Aβ) is the main component of neuritic plaques in Alzheimer’s disease (AD), and its accumulation has been considered as the molecular driver of Alzheimer’s pathogenesis and progression. Aβ has been the prime target for the development of AD therapy. However, the repeated failures o...
Autores principales: | Zhang, Yun, Chen, Huaqiu, Li, Ran, Sterling, Keenan, Song, Weihong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10310781/ https://www.ncbi.nlm.nih.gov/pubmed/37386015 http://dx.doi.org/10.1038/s41392-023-01484-7 |
Ejemplares similares
-
Brain-derived neurotrophic factor in Alzheimer’s disease and its pharmaceutical potential
por: Gao, Lina, et al.
Publicado: (2022) -
Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease
por: Lannfelt, Lars, et al.
Publicado: (2014) -
An “Amyloid‐β Cleaner” for the Treatment of Alzheimer's Disease by Normalizing Microglial Dysfunction
por: Liu, Ruiyuan, et al.
Publicado: (2019) -
Gonadotropin releasing hormone (GnRH): a hormone therapy boosts cognition in Down syndrome and dementia
por: Sterling, Keenan, et al.
Publicado: (2023) -
β-Amyloid Degradation and Alzheimer's Disease
por: Wang, Deng-Shun, et al.
Publicado: (2006)